Rocket Pharmaceuticals Inc [RCKT] stock is trading at $11.08, up 4.92%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RCKT shares have gain 4.73% over the last week, with a monthly amount drifted -12.89%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Rocket Pharmaceuticals Inc [NASDAQ: RCKT] stock has seen the most recent analyst activity on December 30, 2024, when Wedbush initiated its Outperform rating and assigned the stock a price target of $32. Previously, Jefferies started tracking the stock with Buy rating on December 18, 2024, and set its price target to $29. On October 16, 2024, Scotiabank initiated with a Sector Outperform rating. Goldman started tracking the stock assigning a Neutral rating and suggested a price target of $39 on April 02, 2024. Cantor Fitzgerald initiated its recommendation with a Overweight and recommended $65 as its price target on October 24, 2023. Morgan Stanley started tracking with a Overweight rating for this stock on February 01, 2023, and assigned it a price target of $45. In a note dated November 08, 2022, Canaccord Genuity initiated an Buy rating and provided a target price of $53 on this stock.
Rocket Pharmaceuticals Inc [RCKT] stock has fluctuated between $10.07 and $31.47 over the past year. Currently, Wall Street analysts expect the stock to reach $38.67 within the next 12 months. Rocket Pharmaceuticals Inc [NASDAQ: RCKT] shares were valued at $11.08 at the most recent close of the market. An investor can expect a potential return of 249.01% based on the average RCKT price forecast.
Analyzing the RCKT fundamentals
Gross Profit Margin for this corporation currently stands at 0.05% with Operating Profit Margin at -26.55%, Pretax Profit Margin comes in at -25.03%, and Net Profit Margin reading is -25.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.66, Equity is -0.63 and Total Capital is -0.77. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.65 points at the first support level, and at 10.22 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.32, and for the 2nd resistance point, it is at 11.57.
Ratios To Look Out For
For context, Rocket Pharmaceuticals Inc’s Current Ratio is 6.05. Further, the Quick Ratio stands at 6.05, while the Cash Ratio is 1.64.
Transactions by insiders
Recent insider trading involved White Mark Andrew, Former Officer, that happened on Jan 31 ’25 when 2824.0 shares were purchased., Militello John completed a deal on Jan 23 ’25 to sell 896.0 shares. Meanwhile, Officer Militello John bought 896.0 shares on Jan 23 ’25.
